Propensity of Fluoroquinolones with Different Moieties at Position 8 to Cause Resistance Development in Clinical Isolates of
            <b>
              <i>Streptococcus pneumoniae</i>
            </b>

Schmitz, F.-J.; Boos, Mechthild; Mayer, S.; Häfner, D.; Jagusch, Harold; Verhoef, J.; Fluit, Ad C.

doi:10.1128/aac.45.9.2666-2667.2001

Cited by 20 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, further information concerning the in vivo efficacy of new fluoroquinolones is needed. Especially, the risk of in vivo mutations has to be investigated, taking into account the high in vitro rate of mutation of pneumococci when exposed to quinolones (1,6,41,42,45,46,55,66,68,74) compared to beta-lactam agents.…”

mentioning

confidence: 99%

Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy

Croisier¹,

Etienne²,

Bergoin³

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

mentioning

confidence: 99%

Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy

Croisier¹,

Etienne²,

Bergoin³

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…36 Several experimental studies have demonstrated that these 8-methoxyfluoroquino- lones may have a lower propensity to select for resistant S. pneumoniae than do ciprofloxacin, levofloxacin and other older fluoroquinolones. [37][38][39] Initial Fuoroquinolone Experience in AOM. Gatifloxacin, which was approved in the United States in 1999 for use in adults, is effective and well-tolerated for treatment of community-acquired respiratory tract infections such as pneumonia, acute exacerbations of chronic bronchitis and acute bacterial rhinosinusitis.…”

Section: Potential Role Of Fluoroquinolones In Rommentioning

confidence: 99%

Potential Role of Fluoroquinolone Therapy in Childhood Otitis Media

Dagan

Arguedas²,

Schaad³

2004

The Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Increased resistance of pneumococci and other pathogens to available antibiotics raises concerns about bacteriologic and clinical failure in children with acute otitis media. Few therapeutic options exist for patients with recurrent infections or recent treatment failure. The limited experience from the compassionate use of fluoroquinolones in pediatrics and pediatric studies has not been linked unequivocally with arthrotoxicity, the primary safety concern in children. Newer 8-methoxyfluoroquinolones may have a role in selected cases associated with multidrug-resistant pathogens.

show abstract

“…Although this concern is not quinolone-specific and should apply to all the antimicrobial families, it should be acknowledged that resistance to gatifloxacin requires mutations in two different target proteins, which is clearly less likely to occur than mutations leading to resistance in other antibiotics, such as penicillins or macrolides [85]. Moreover in vitro experiments have shown that selection of quinolone-resistant strains of S. pneumoniae occurs less frequently with the 8-methoxyfluoroquinolones gatifloxacin and moxifloxacin than with other fluoroquinolones, such as ciprofloxacin and levofloxacin [86,87].…”

Section: Otitis Mediamentioning

confidence: 99%

Fluoroquinolones in Pediatrics

Arguedas¹,

Sierra²,

Soley³

2006

CDTH

View full text Add to dashboard Cite

The fluoroquinolones (FQ) are a group of antimicrobials with a broad spectrum of activity against gram positive and gram negative organisms, intracellular and anaerobic organisms. These antimicrobial agents have excellent oral bioavailability, high tissue penetration, low protein binding and a long elimination half life. The experience with these antibiotics in children has been limited to certain conditions mainly in the treatment of bronchopulmonary exacerbations in children with cystic fibrosis and in the ambulatory treatment of children with fever and neutropenia. Despite the limited use, it is recognize that there are other potential indications for the use of FQ in pediatrics such as for the treatment of children with bacterial meningitis, refractory and recurrent otitis media, pneumonia, multiply resistant salmonellosis and shigellosis and complicated urinary tract infections. Furthermore, the new FQ have shown excellent invitro activity against penicillin-resistant Streptococcus pneumoniae suggesting that these agents may be an attractive alternative for the treatment of conditions that involve these problematic strains. Cartilage toxicity due to FQ had been a major concern however; the previous experience with ciprofloxacin and recently the results from long term (12 months) prospective studies have found no evidence of such a problem in children. Ciprofloxacin was recently approved for the treatment of children with complicated urinary tract infections. If based on the safety and clinical results of ongoing clinical trials, other new FQ are approved for the treatment of other conditions in children, particularly respiratory tract diseases, caution is highly recommended to avoid selection of bacterial resistance.

show abstract

Propensity of Fluoroquinolones with Different Moieties at Position 8 to Cause Resistance Development in Clinical Isolates of Streptococcus pneumoniae

Cited by 20 publications

References 8 publications

Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy

Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy

Potential Role of Fluoroquinolone Therapy in Childhood Otitis Media

Fluoroquinolones in Pediatrics

Contact Info

Product

Resources

About